

**Cardiovascular Inflammation Reduction Trial (CIRT). A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events**

**Category**

Other

**Enrollment Closing Date**

June 30, 2017

**Description**

This study is sponsored by The National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, in collaboration with medical clinics across the world. Dr. Henry and associates are conducting a research study to determine if using FDA-approved methotrexate reduces heart attacks, strokes, or death in people who have either type 2 diabetes or metabolic syndrome AND have stable coronary artery disease. (CIRT Trial)

**Requirements**

You may be eligible if you are an adult with type 2 diabetes or have a metabolic syndrome and have had a heart attack within the past 5 years or blockage of more than 1 heart artery, including blockages treated with stents or bypass.

**Benefits**

If eligible, you can contribute to cutting-edge research while receiving free study drug, care, safety laboratory samples, and chest x-ray (if one has not been performed within the past year).

**Contact  
Information****Name** Jennifer St. Martin**Phone** 858-552-8585 x 2711